High hydrostatic pressure (HHP) induces immunogenic death of tumor cells which confer protective anti-tumor immunity in vivo. Moreover, DC pulsed with HHP-treated tumor cells induced therapeutic effect in mouse cancer model. In this study, we tested the immunogenicity, stability and T cell stimulatory activity of human monocyte-derived dendritic cell (DC)-based HHP lung cancer vaccine generated in GMP compliant serum free medium using HHP 250 MPa. DC pulsed with HHP-killed lung cancer cells and poly(I:C) enhanced DC maturation, chemotactic migration and production of pro-inflammatory cytokines after 24h. Moreover, DC-based HHP lung cancer vaccine showed functional plasticity after transfer into serum-containing media and stimulation with LPS or CD40L after additional 24h. LPS and CD40L stimulation further differentially enhanced the expression of costimulatory molecules and production of IL-12p70. DC-based HHP lung cancer vaccine decreased the number of CD4+CD25+Foxp3+ T regulatory cells and stimulated IFN-γ-producing tumor antigen-specific CD4+ and CD8+ T cells from non-small cell lung cancer (NSCLC) patients. Tumor antigen specific CD8+ and CD4+ T cell responses were detected in NSCLC patient's against a selected tumor antigens expressed by lung cancer cell lines used for the vaccine generation. We also showed for the first time that protein antigen from HHP-killed lung cancer cells is processed and presented by DC to CD8+ T cells. Our results represent important preclinical data for ongoing NSCLC Phase I/II clinical trial using DC-based active cellular immunotherapy (DCVAC/LuCa) in combination with chemotherapy and immune enhancers.

Department of Immunology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

SOTIO Prague Czech Republic

Thoracic and Lung Transplantation Division 3rd Department of Surgery 1st Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Zobrazit více v PubMed

Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung cancer. 2011;73(1):11–7. 10.1016/j.lungcan.2011.02.023 PubMed DOI

Skachkova OV, Khranovska NM, Gorbach OI, Svergun NM, Sydor RI, Nikulina VV. Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer. Experimental oncology. 2013;35(2):109–13. PubMed

Datta J, Terhune JH, Lowenfeld L, Cintolo JA, Xu S, Roses RE et al. Optimizing dendritic cell-based approaches for cancer immunotherapy. The Yale journal of biology and medicine. 2014;87(4):491–518. PubMed PMC

Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ et al. Immunobiology of dendritic cells. Annual review of immunology. 2000;18:767–811. 10.1146/annurev.immunol.18.1.767 PubMed DOI

Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(17):8078–82. PubMed PMC

Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer immunology, immunotherapy: CII. 2013;62(1):137–47. 10.1007/s00262-012-1317-2 PubMed DOI PMC

Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Yano Y et al. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. International journal of oncology. 2004;24(4):909–17. PubMed

Perroud MW Jr., Honma HN, Barbeiro AS, Gilli SC, Almeida MT, Vassallo J et al. Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study. Journal of experimental & clinical cancer research: CR. 2011;30:65. PubMed PMC

Babatz J, Rollig C, Lobel B, Folprecht G, Haack M, Gunther H et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer immunology, immunotherapy: CII. 2006;55(3):268–76. 10.1007/s00262-005-0021-x PubMed DOI PMC

Takahashi H, Okamoto M, Shimodaira S, Tsujitani S, Nagaya M, Ishidao T et al. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers. European journal of cancer. 2013;49(4):852–9. 10.1016/j.ejca.2012.11.005 PubMed DOI

Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005;11(8):3017–24. PubMed

Kontani K, Taguchi O, Ozaki Y, Hanaoka J, Sawai S, Inoue S et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. International journal of molecular medicine. 2003;12(4):493–502. PubMed

Chang GC, Lan HC, Juang SH, Wu YC, Lee HC, Hung YM et al. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer. 2005;103(4):763–71. 10.1002/cncr.20843 PubMed DOI

Engell-Noerregaard L, Hendel HW, Johannesen HH, Alslev L, Svane IM. FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma. Cancer immunology, immunotherapy: CII. 2013;62(1):17–25. 10.1007/s00262-012-1306-5 PubMed DOI PMC

Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004;22(14):2808–15. PubMed

Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung cancer. 2007;57(3):365–72. 10.1016/j.lungcan.2007.04.002 PubMed DOI PMC

Yannelli JR, Sturgill J, Foody T, Hirschowitz E. The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC). Lung cancer. 2005;47(3):337–50. 10.1016/j.lungcan.2004.08.008 PubMed DOI

Hirschowitz EA, Mullins A, Prajapati D, Baeker T, Kloecker G, Foody T et al. Pilot study of 1650-G: a simplified cellular vaccine for lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2011;6(1):169–73. PubMed

Um SJ, Choi YJ, Shin HJ, Son CH, Park YS, Roh MS et al. Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer. Lung cancer. 2010;70(2):188–94. 10.1016/j.lungcan.2010.02.006 PubMed DOI

Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annual review of immunology. 2013;31:51–72. 10.1146/annurev-immunol-032712-100008 PubMed DOI

Adkins I, Fucikova J, Garg AD, Agostinis P, Spisek R. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology. 2014;3(12):e968434 10.4161/21624011.2014.968434 PubMed DOI PMC

Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L et al. Molecular characteristics of immunogenic cancer cell death. Cell death and differentiation. 2008;15(1):3–12. 10.1038/sj.cdd.4402269 PubMed DOI

Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nature reviews Cancer. 2012;12(12):860–75. 10.1038/nrc3380 PubMed DOI

Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. International journal of cancer Journal international du cancer. 2014;135(5):1165–77. 10.1002/ijc.28766 PubMed DOI

Mikyskova R, Stepanek I, Indrova M, Bieblova J, Simova J, Truxova I et al. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. International journal of oncology. 2016;48(3):953–64. 10.3892/ijo.2015.3314 PubMed DOI PMC

Truxova I, Pokorna K, Kloudova K, Partlova S, Spisek R, Fucikova J. Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs. Immunology letters. 2014;160(1):39–49. 10.1016/j.imlet.2014.03.010 PubMed DOI

Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005;11(22):8055–62. PubMed

Karanikas V, Tsochas S, Boukas K, Kerenidi T, Nakou M, Dahabreh J et al. Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: implications for immunotherapy. Cancer biology & therapy. 2008;7(3):345–52. PubMed

Tajima K, Obata Y, Tamaki H, Yoshida M, Chen YT, Scanlan MJ et al. Expression of cancer/testis (CT) antigens in lung cancer. Lung cancer. 2003;42(1):23–33. PubMed

Grunwald C, Koslowski M, Arsiray T, Dhaene K, Praet M, Victor A et al. Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. International journal of cancer Journal international du cancer. 2006;118(10):2522–8. 10.1002/ijc.21669 PubMed DOI

Fucikova J, Rozkova D, Ulcova H, Budinsky V, Sochorova K, Pokorna K et al. Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. Journal of translational medicine. 2011;9:223 10.1186/1479-5876-9-223 PubMed DOI PMC

West MA, Wallin RP, Matthews SP, Svensson HG, Zaru R, Ljunggren HG et al. Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science. 2004;305(5687):1153–7. 10.1126/science.1099153 PubMed DOI

Macagno A, Napolitani G, Lanzavecchia A, Sallusto F. Duration, combination and timing: the signal integration model of dendritic cell activation. Trends in immunology. 2007;28(5):227–33. 10.1016/j.it.2007.03.008 PubMed DOI

Abdi K, Singh NJ, Matzinger P. Lipopolysaccharide-activated dendritic cells: "exhausted" or alert and waiting? Journal of immunology. 2012;188(12):5981–9. PubMed PMC

Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. The Journal of experimental medicine. 1996;184(2):747–52. PubMed PMC

Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. Seminars in immunology. 2009;21(5):265–72. 10.1016/j.smim.2009.05.010 PubMed DOI PMC

Rouas R, Lewalle P, El Ouriaghli F, Nowak B, Duvillier H, Martiat P. Poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12. International immunology. 2004;16(5):767–73. 10.1093/intimm/dxh077 PubMed DOI

Delamarre L, Holcombe H, Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. The Journal of experimental medicine. 2003;198(1):111–22. 10.1084/jem.20021542 PubMed DOI PMC

Alanio C, Lemaitre F, Law HK, Hasan M, Albert ML. Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. Blood. 2010;115(18):3718–25. 10.1182/blood-2009-10-251124 PubMed DOI

Coulie PG, Connerotte T. Human tumor-specific T lymphocytes: does function matter more than number? Current opinion in immunology. 2005;17(3):320–5. 10.1016/j.coi.2005.03.002 PubMed DOI

He XS, Mahmood K, Maecker HT, Holmes TH, Kemble GW, Arvin AM et al. Analysis of the frequencies and of the memory T cell phenotypes of human CD8+ T cells specific for influenza A viruses. The Journal of infectious diseases. 2003;187(7):1075–84. 10.1086/368218 PubMed DOI

Takahashi N, Ohkuri T, Homma S, Ohtake J, Wakita D, Togashi Y et al. First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer science. 2012;103(1):150–3. 10.1111/j.1349-7006.2011.02106.x PubMed DOI PMC

Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. Journal of immunology. 2004;172(5):3289–96. PubMed

Brunsvig PF, Kyte JA, Kersten C, Sundstrom S, Moller M, Nyakas M et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011;17(21):6847–57. PubMed

Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood. 2007;109(12):5346–54. 10.1182/blood-2006-10-051318 PubMed DOI PMC

Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications

Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells